Did you know?
You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)
Re: ESC 2019 Symposium: Epigenetics: A new pathway to tackle residual risk?
Clinical update on BET inhibition: The patient profile that may benefit from BET inhibition?,Kausik Ray, MD, London, United Kingdom
I wonder if this will apply to zen3694 in the mCRPC trial in determining the characteristics of trial patients that have responded so well in the trial with enzalutimide and aberaterone?
